A federal judge in Santa Rosa has ordered the health plan for Argentina’s national university workers to authorize critical radiotherapy within 48 hours, following the insurer’s decision to approve chemotherapy while refusing the concurrent radiation treatment required for the patient’s survival.
Federal Judge Juan José Baric ruled that the two therapies are medically indivisible for J. J. S., a 51-year-old patient diagnosed in 2022 with squamous cell carcinoma of the lower right lip. A recent locoregional cervicothoracic recurrence has produced a significant tumor mass in the neck and chest, compromising deep muscles, extending toward the sternal manubrium and displacing the trachea.
The treating oncologist, Dr. Sebastián García Peralbo, prescribed weekly chemotherapy alongside external beam radiotherapy using VMAT/IMRT technology with daily image guidance, to be delivered in 35 fractions over seven weeks, according to El Diario de la Pampa.
“Each day of delay favored tumor growth and reduced the chances of locoregional disease control,” Dr. Sebastián García Peralbo said.
Because the treatments are concurrent and indivisible, the approved chemotherapy could not start without the radiotherapy authorization.
After an urgent administrative claim filed on October 28, 2026, received no formal response, the patient filed an amparo action with a precautionary measure to innovate, represented by attorney Esteban Torroba. Federal Prosecutor Iara J. Silvestre supported the jurisdiction and the admissibility of the writ.
“The right to health has the maximum protection in the National Constitution (arts. 14 bis and 75 incs. 22 and 23) and in international human rights treaties,” Judge Baric wrote in the ruling.
The court found the likelihood of the right proven by the medical evidence and the danger in delay demonstrated by the tumor volume displacing the trachea and the risk of local complications.
OSFATUN — Obra Social de la Federación Argentina del Trabajador de las Universidades Nacionales — is the mandatory health plan for dependent employees of Argentina’s national universities, identified in the Registro Nacional de Agentes del Seguro de la SSSalud with code 125509 (RNAS 1-2550-9) as of September 2026.
It operates its own network of pharmacies and specialized circuits, including an oncology pathway under “Medicamentos de alto costo” that requires forms, medical orders, and supporting studies evaluated by Auditoría Médica with final purchase and delivery managed by Casa Central within 8–10 business days.
The court ordered OSFATUN to grant 100% coverage of the prescribed VMAT/IMRT radiotherapy within 48 hours, ensuring its immediate start concurrent with chemotherapy. The measure lasts 90 days or until a final sentence. The tribunal also granted the benefit of gratuity under Article 53 of Law 24.240, accepted the sworn bond, and gave the insurer five days to answer the amparo report.